The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis

References

• Pradas I, Rovira-Llopis S, Naudí A, et al. Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women. Sci Rep. 2019;9(1):16033.
   PubMedGoogle Scholar
• Manzoor S, Ganie MA, Amin S, et al. Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: an observational study. Sci Rep. 2019;9(1):10182.
   PubMedGoogle Scholar
• Christianson MS, Wu H, Zhao Y, et al. Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey. J Assist Reprod Genet. 2015;32(3):401–406.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Altinok ML, Ravn P, et al. Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS. Endocr Connect. 2018;7(3):479–489.
   PubMed Web of Science ®Google Scholar
• Kokosar M, Benrick A, Perfilyev A, et al. A single bout of electroacupuncture remodels epigenetic and transcriptional changes in adipose tissue in polycystic ovary syndrome. Sci Rep. 2018;8(1):1878.
   PubMedGoogle Scholar
• Haidari F, Banaei-Jahromi N, Zakerkish M, et al. The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial. Nutr J. 2020;19(1):8.
   PubMed Web of Science ®Google Scholar
• Banshoya K, Nakamura T, Tanaka T, et al. Coenzyme Q10-polyethylene glycol monostearate nanoparticles: an injectable water-soluble formulation. Antioxidants (Basel, Switzerland). 2020;9(1):86.
   Google Scholar
• Farboud ES, Nasrollahi SA, Tabbakhi Z. Novel formulation and evaluation of a Q10-loaded solid lipid nanoparticle cream: in vitro and in vivo studies. Int J Nanomed. 2011;6:611–617.
   PubMed Web of Science ®Google Scholar
• Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130(Pt 8):2037–2044.
   PubMedGoogle Scholar
• Wong SK, Chin K-Y, Suhaimi FH, et al. Vitamin E as a potential interventional treatment for metabolic syndrome: evidence from animal and human studies. Front Pharmacol. 2017;8:444.
   PubMed Web of Science ®Google Scholar
• Ostadmohammadi V, Jamilian M, Bahmani F, et al. Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome. J Ovarian Res. 2019;12(1):5.
   PubMedGoogle Scholar
• Laganà AS, Garzon S, Casarin J, et al. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol Metab. 2018;29(11):768–780.
   PubMed Web of Science ®Google Scholar
• Pundir J, Psaroudakis D, Savnur P, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299–308.
   PubMedGoogle Scholar
• Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;59(1):30–38.
   PubMed Web of Science ®Google Scholar
• Pergialiotis V, Karampetsou N, Panagopoulos P, et al. The effect of Vitamin D supplementation on hormonal and glycaemic profile of patients with PCOS: a meta-analysis of randomised trials. Int J Clin Pract. 2017;71(6):e12957.
   Web of Science ®Google Scholar
• Łagowska K, Bajerska J, Jamka M. The role of vitamin D oral supplementation in insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2018;10(11):1637.
   Web of Science ®Google Scholar
• Azadi-Yazdi M, Nadjarzadeh A, Khosravi-Boroujeni H, et al. The effect of vitamin D supplementation on the androgenic profile in patients with polycystic ovary syndrome: a systematic review and meta-analysis of clinical trials. Horm Metab Res. 2017;49(3):174–179.
   PubMed Web of Science ®Google Scholar
• Zawadri JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome: current issues in endocrinology and metabolism. Boston (MA): Black-well Scientific; 1992.
   Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–488.
   PubMed Web of Science ®Google Scholar
• Higgins J, Sterne J, Savović J, et al. A revised tool for assessing risk of bias in randomized trails. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Database of Systematic Reviews. 2016;10(Suppl 1):29–31.
   Google Scholar
• Zhang L, Zhang M, Zhang Y, et al. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904.
   PubMed Web of Science ®Google Scholar
• Du J, Wu R, Lin X, et al. Clinical effect of myo-inositol combined with D-chiro-inositol on insulin resistant polycystic ovary syndrome. China Med. 2018;13(9):1389–1393.
   Google Scholar
• Benelli E, Del Ghianda S, Di Cosmo C, et al. A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016;2016:3204083.
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol off J Int Soc Gynecol Endocrinol. 2013;29(4):375–379.
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105–110.
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417–423.
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314–1320.
   PubMed Web of Science ®Google Scholar
• Izadi A, Ebrahimi S, Shirazi S, et al. Hormonal and metabolic effects of coenzyme Q10 and/or vitamin E in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(2):319–327.
   PubMed Web of Science ®Google Scholar
• Izadi A, Shirazi S, Taghizadeh S, et al. Independent and additive effects of coenzyme Q10 and vitamin E on cardiometabolic outcomes and visceral adiposity in women with polycystic ovary syndrome. Arch Med Res. 2019;50(2):1–10.
   PubMed Web of Science ®Google Scholar
• Samimi M, Zarezade Mehrizi M, Foroozanfard F, et al. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2017;86(4):560–566.
   PubMed Web of Science ®Google Scholar
• Ying XC. Effect of coenzyme Q10 combined with vitamin E on glucose metabolism indexes and levels of sex hormones in patients with polycystic ovary syndrome. Matern Child Heal Care China. 2019;34(20):4747–4750.
   Google Scholar
• Tao LU, Jianmin H, Juan Q, et al. Effect of coenzyme Q10 combined with vitamin E on metabolism and hormone in patients with polycystic ovary syndrome. China Med Eng. 2020;28(01):16–20.
   Google Scholar
• Rahmani E, Jamilian M, Samimi M, et al. The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome. Gynecol Endocrinol off J Int Soc Gynecol Endocrinol. 2018;34(3):217–222.
   PubMed Web of Science ®Google Scholar
• Seyyed Abootorabi M, Ayremlou P, Behroozi-Lak T, et al. The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial. Gynecol Endocrinol off J Int Soc Gynecol Endocrinol. 2018;34(6):489–494.
   PubMed Web of Science ®Google Scholar
• Ardabili HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. 2012;32(3):195–201.
   PubMed Web of Science ®Google Scholar
• Bonakdaran S, Mazloom Khorasani Z, Davachi B, et al. J. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. Iran J Reprod Med. 2012;10(5):465–472.
   PubMedGoogle Scholar
• Raja-Khan N, Shah J, Stetter CM, et al. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril. 2014;101(6):1740–1746.
   PubMed Web of Science ®Google Scholar
• Jamilian M, Foroozanfard F, Rahmani E, et al. Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients. 2017;9(12):1280.
   Web of Science ®Google Scholar
• Irani M, Seifer DB, Grazi RV, et al. Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2015;100(11):4307–4314.
   PubMed Web of Science ®Google Scholar
• Asemi Z, Foroozanfard F, Hashemi T, et al. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clin Nutr. 2015;34(4):586–592.
   PubMed Web of Science ®Google Scholar
• Maktabi M, Chamani M, Asemi Z. The effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Horm Metab Res. 2017;49(07):493–498.
   PubMedGoogle Scholar
• Javed Z, Papageorgiou M, Deshmukh H, et al. A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients. 2019;11(1):188.
   Web of Science ®Google Scholar
• Rahimi-Ardabili H, Pourghassem Gargari B, Farzadi L. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. J Endocrinol Invest. 2013;36(1):28–32.
   PubMed Web of Science ®Google Scholar
• Jafari-Sfidvajani S, Ahangari R, Hozoori M, et al. The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. J Endocrinol Invest. 2018;41(5):597–607.
   PubMed Web of Science ®Google Scholar
• Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111–117.
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci. 2014;21(7):854–858.
   PubMed Web of Science ®Google Scholar
• Wojciechowska A, Osowski A, Jóźwik M, et al. Inositols’ importance in the improvement of the endocrine-metabolic profile in PCOS. IJMS. 2019;20(22):5787.
   Google Scholar
• Schroeder MM, Belloto RJJ, Hudson RA, et al. Effects of antioxidants coenzyme Q10 and lipoic acid on interleukin-1 beta-mediated inhibition of glucose-stimulated insulin release from cultured mouse pancreatic islets. Immunopharmacol Immunotoxicol. 2005;27(1):109–122.
   PubMed Web of Science ®Google Scholar